Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Accumulated Expenses (2016 - 2025)

Traws Pharma (TRAW) has disclosed Accumulated Expenses for 14 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 83.23% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, up 83.23%, while the annual FY2025 figure was $4.3 million, 83.23% up from the prior year.
  • Accumulated Expenses hit $4.3 million in Q4 2025 for Traws Pharma, up from $2.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $4.3 million in Q4 2025 and bottomed at $502000.0 in Q2 2025.
  • Average Accumulated Expenses over 5 years is $2.4 million, with a median of $2.6 million recorded in 2022.
  • Year-over-year, Accumulated Expenses surged 277.04% in 2024 and then plummeted 80.46% in 2025.
  • Traws Pharma's Accumulated Expenses stood at $1.2 million in 2021, then surged by 225.39% to $4.0 million in 2022, then fell by 14.77% to $3.4 million in 2023, then tumbled by 30.93% to $2.3 million in 2024, then skyrocketed by 83.23% to $4.3 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $4.3 million, $2.8 million, and $502000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.